clyde on the point of losing control didnt we have the same issue years ago with losing control over clinical trial information on Artimist from ProtoPharma. I seem to recall reading it in annual reports for 2011 though to 2014.
SUD Price at posting:
0.6¢ Sentiment: Hold Disclosure: Held